Publication | Closed Access

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

UrologyGenitourinary CancerMedicineBevacizumab Versus SunitinibImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyMolecular OncologyPhase 3